Clozapine in the Current Management of Schizophrenia

Clozapine in the Current Management of Schizophrenia
Overview

Clozapine, the “prototypical atypical” (i.e., first atypical), or second-generation antipsychotic (SGA), was originally synthesized in 1958.1 It was first introduced in Europe in the early 1970s, but was withdrawn from the market in 1975 due to concerns over a low but significant risk of agranulocytosis compared to other antipsychotics.2 In the late 1980s a study demonstrated the clinical superiority of clozapine over other antipsychotics in the treatment of refractory schizophrenia.2

This program provides insight into the role of clozapine in the treatment of resistant schizophrenia with respect to efficacy, tolerability, monitoring, drug interactions, and initiation of the medication.


Disclosures: All three of the authors wish to declare some form of conflict of interest as either a member of an advisory board or speaker’s bureau, a recipient of funds, a paid speaker or participant in clinical research for sponsors, including Mylan. One of the expert reviewers declares that he has been a paid speaker, member of an advisory board or part of clinical research for sponsors other than this one.






This program has been supported by an educational grant from Mylan Pharmaceuticals ULC.
$0.00
2.00 CEU
 
Author

Dr. Pierre Chue
FRCPC

Dr. Toba Oluboka
FRCPC

Ron Pohar
BScPharm

Reviewers

Michael Boivin
BScPhm, CDE, CTE, CTH

Jamie Kellar
BScHK, BScPharm, PharmD

1057-2017-2249-I-P
(Expires: 31-Mar-2019)